JPH11512736A - N−プロパルギル−1−アミノインダンを含有する安定な組成物 - Google Patents
N−プロパルギル−1−アミノインダンを含有する安定な組成物Info
- Publication number
- JPH11512736A JPH11512736A JP9514119A JP51411997A JPH11512736A JP H11512736 A JPH11512736 A JP H11512736A JP 9514119 A JP9514119 A JP 9514119A JP 51411997 A JP51411997 A JP 51411997A JP H11512736 A JPH11512736 A JP H11512736A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- propargyl
- composition according
- aminoindan
- alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 活性成分としてラセミ体、S(−)、及びR(+)−N−プロパルギル −1−アミノインダンの群から選択される構成要素である化合物又はこれらの薬 学的に許容しうる塩の治療に効果的な量、及び少なくとも60重量%の、五価及 び六価アルコールの群から選択される構成要素である少なくとも1つのアルコー ルを含有する薬学的組成物。 2. 請求の範囲第1項に記載の薬学的組成物であって、少なくとも70重量 %の前記の少なくとも1つのアルコールを含有するもの。 3. 請求の範囲第1項又は2項に記載の薬学的組成物であって、前記の少な くとも1つのアルコールがマンニトール、キシリトール及びソルビトールの群か ら選択される構成要素であるもの。 4. 請求の範囲第1項から第3項の何れか1項に記載の薬学的組成物であっ て、クエン酸を更に含有するもの。 5. 請求の範囲第4項に記載の薬学的組成物であって、クエン酸の量が0. 5から2重量%であるもの。 6. 請求の範囲第1項から第5項の何れか1項に記載の薬学的組成物であっ て、ステアリン酸マグネシウムを更に含有するもの。 7. 請求の範囲第6項に記載の薬学的組成物であって、ステアリン酸マグネ シウムの量が0.1から0.5重量%であるもの。 8. 請求の範囲第6項又は7項に記載の薬学的組成物であって、前記の少な くとも1つのアルコールの量が70%以下であり、クエン酸を更に含有するもの 。 9. 請求の範囲第1項から第8項の何れか1項に記載の薬学的組成物であっ て、前記活性成分がR(+)−N−プロパルギル−1−アミノインダンであるも の。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL115357 | 1995-09-20 | ||
IL11535795A IL115357A (en) | 1995-09-20 | 1995-09-20 | Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols |
PCT/IL1996/000115 WO1997012583A2 (en) | 1995-09-20 | 1996-09-18 | Stable compositions containing n-propargyl-1-aminoindan |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11512736A true JPH11512736A (ja) | 1999-11-02 |
JP4108750B2 JP4108750B2 (ja) | 2008-06-25 |
Family
ID=11068003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51411997A Expired - Lifetime JP4108750B2 (ja) | 1995-09-20 | 1996-09-18 | N−プロパルギル−1−アミノインダンを含有する安定な組成物 |
Country Status (13)
Country | Link |
---|---|
US (1) | US6126968A (ja) |
EP (1) | EP0858328B1 (ja) |
JP (1) | JP4108750B2 (ja) |
AT (1) | ATE362755T1 (ja) |
AU (1) | AU728524B2 (ja) |
CA (1) | CA2232310C (ja) |
DE (1) | DE69637096T2 (ja) |
DK (1) | DK0858328T3 (ja) |
ES (1) | ES2287940T3 (ja) |
HU (1) | HU225859B1 (ja) |
IL (1) | IL115357A (ja) |
PT (1) | PT858328E (ja) |
WO (1) | WO1997012583A2 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008519834A (ja) * | 2004-11-10 | 2008-06-12 | テバ ファーマシューティカル インダストリーズ リミティド | 低水溶性薬物とともに使用することによく適した圧縮固体状投与形態の製造方法およびそれにより製造された圧縮固体状投与形態 |
US8367106B2 (en) | 2004-11-10 | 2013-02-05 | Teva Pharmaceutical Industries, Ltd. | Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby |
JP2013509359A (ja) * | 2009-10-29 | 2013-03-14 | 重▲慶▼医葯工▲業▼研究院有限責任公司 | 安定なラサギリン組成物 |
JP2014534196A (ja) * | 2011-10-10 | 2014-12-18 | テバ ファーマシューティカル インダストリーズ リミティド | R(+)−n−ホルミル−プロパルギル−アミノインダン |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744500A (en) * | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
IL118836A (en) | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
CA2387394C (en) | 1999-10-27 | 2009-08-18 | Teva Pharmaceutical Industries, Ltd. | Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder |
EP2526944B1 (en) * | 2002-11-15 | 2016-06-01 | Teva Pharmaceutical Industries Limited | Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis |
GB2411355B (en) | 2004-02-27 | 2006-02-22 | Niche Generics Ltd | Pharmaceutical composition |
CA2574925A1 (en) * | 2004-07-26 | 2006-02-09 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical dosage forms including rasagiline |
MX2007006199A (es) * | 2004-11-24 | 2007-07-13 | Teva Pharma | Composiciones de desintegracion oral de rasagilina. |
US20100167983A1 (en) * | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
WO2006089164A1 (en) * | 2005-02-17 | 2006-08-24 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
RU2404746C2 (ru) | 2005-02-23 | 2010-11-27 | Тева Фармасьютикал Индастриз, Лтд. | Композиции разагилина с улучшенной однородностью содержимого |
US7491847B2 (en) | 2005-11-17 | 2009-02-17 | Teva Pharmaceutical Industries, Ltd. | Methods for isolating propargylated aminoindans |
US7572834B1 (en) | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
JP2009518433A (ja) | 2005-12-09 | 2009-05-07 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム | 神経保護用の低用量ラドスチギルの使用 |
US8809310B2 (en) | 2006-02-21 | 2014-08-19 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
TW200744576A (en) | 2006-02-24 | 2007-12-16 | Teva Pharma | Propargylated aminoindans, processes for preparation, and uses thereof |
AU2007235517B2 (en) * | 2006-04-03 | 2013-01-31 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of Restless Legs Syndrome |
DE202006020710U1 (de) | 2006-05-09 | 2009-12-31 | Teva Pharmaceutical Industries Ltd. | Zusammensetzungen mit Rosiglitazonmaleat |
EP1892233A1 (de) * | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
BRPI0718339A2 (pt) | 2006-12-14 | 2014-02-18 | Teva Pharma | Composto, composição, composição farmacêutica e processo de fabricação de tanato de rasagilina |
CA2672414A1 (en) * | 2006-12-14 | 2008-06-26 | Teva Pharmaceutical Industries Ltd. | Crystalline solid rasagiline base |
EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
CA2698695A1 (en) * | 2007-09-05 | 2009-03-12 | Teva Pharmaceutical Industries Ltd. | Method of treating glaucoma using rasagiline |
US8188149B2 (en) * | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
CN101909438A (zh) * | 2008-01-11 | 2010-12-08 | 泰华制药工业有限公司 | 雷沙吉兰制剂、其制备及用途 |
US20090247537A1 (en) * | 2008-03-25 | 2009-10-01 | William Dale Overfield | Methods for preventing or treating bruxism using dopaminergic agents |
EP2271612B1 (en) * | 2008-03-31 | 2016-08-10 | Actavis Group PTC EHF | Rasagiline mesylate particles and process for the preparation thereof |
NZ589445A (en) * | 2008-06-13 | 2013-06-28 | Teva Pharma | Rasagiline for parkinson's disease modification |
WO2009154777A2 (en) * | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries, Ltd. | Process for preparing and drying solid rasagiline base |
US8334409B2 (en) * | 2008-06-19 | 2012-12-18 | Teva Pharmaceutical Industries, Ltd. | Process for purifying rasagiline base |
US20100189791A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline malate formulation |
EP2218444A3 (en) | 2009-01-23 | 2010-08-25 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
EP2403485A2 (en) | 2009-03-05 | 2012-01-11 | Sandoz AG | Pharmaceutical composition containing rasagiline mesylate |
JP2012532843A (ja) | 2009-07-09 | 2012-12-20 | ラティオファーム ゲーエムベーハー | ラサギリンの塩およびその製剤 |
EP2515891A4 (en) | 2009-12-22 | 2013-06-05 | Teva Pharma | 3-keto-N-propargyl-1-aminoindan |
EP2563347B1 (en) | 2010-04-30 | 2016-10-12 | Teikoku Pharma USA, Inc. | Propynylaminoindan transdermal compositions |
EP2389927A1 (en) | 2010-05-30 | 2011-11-30 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Pharmaceutical formulations of rasagiline |
WO2012015946A1 (en) | 2010-07-27 | 2012-02-02 | Teva Pharmaceutical Industries Ltd. | Dispersion of rasagiline citrate |
JP2013533287A (ja) | 2010-07-27 | 2013-08-22 | テバ ファーマシューティカル インダストリーズ リミティド | 嗅覚機能不全の処置のためのラサギリンの使用 |
CN103476404B (zh) | 2011-03-24 | 2017-09-29 | 帝国制药美国公司 | 包含活性剂层和活性剂转化层的透皮组合物 |
JP2014534197A (ja) | 2011-10-10 | 2014-12-18 | テバ ファーマシューティカル インダストリーズ リミティド | R(+)−n−メチル−プロパルギルアミノインダン |
CA2851274A1 (en) * | 2011-10-10 | 2013-04-18 | Konstantin Ulanenko | Rasagiline citramide |
WO2013070526A1 (en) | 2011-11-09 | 2013-05-16 | Teikoku Pharma Usa, Inc. | Methods for the treatment of skin neoplasms |
DE102012000786A1 (de) | 2012-01-18 | 2013-07-18 | Stada Arzneimittel Ag | Verfahren zur Herstellung einer festen pharmazeutischen Zusammensetzung, enthaltend den Wirkstoff Rasagilin |
EP2827848B1 (en) | 2012-03-21 | 2016-04-27 | Synthon BV | Stabilized pharmaceutical compositions comprising rasagiline salts |
WO2013175493A1 (en) | 2012-04-09 | 2013-11-28 | Cadila Healthcare Limited | Stable oral pharmaceutical compositions |
AR092168A1 (es) | 2012-08-17 | 2015-03-25 | Teva Pharma | Formulaciones parenterales de rasagilina |
SG11201502681WA (en) | 2012-11-02 | 2015-05-28 | Teikoku Pharma Usa Inc | Propynylaminoindan transdermal compositions |
ES2502140T1 (es) * | 2013-02-06 | 2014-10-02 | Galenicum Health S.L. | Comprimidos de liberación inmediata de rasagilina hemitartrato |
ES2524865T1 (es) * | 2013-02-06 | 2014-12-15 | Galenicum Health S.L. | Composiciones farmacéuticas estables en forma de comprimidos de liberación inmediata |
CN115400090A (zh) * | 2022-10-09 | 2022-11-29 | 北京新领先医药科技发展有限公司 | 一种雷沙吉兰的口崩片组合物及其制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1187017A (en) * | 1966-07-16 | 1970-04-08 | Aspro Nicholas Ltd | Substituted 1-Amino Indanes and Tetrahydronaphthalens |
GB8909793D0 (en) * | 1989-04-28 | 1989-06-14 | Beecham Group Plc | Pharmaceutical formulation |
IL92952A (en) * | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
CA2039742A1 (en) * | 1990-04-23 | 1991-10-24 | Andrew B. Dennis | Tablet composition and method for problem pharmaceutical materials |
IL112819A (en) * | 1991-10-16 | 2001-11-25 | Teva Pharma | Fluorinated 1-aminoindan compounds and a process for their preparation |
IL111240A (en) * | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
IL112779A (en) * | 1994-03-01 | 1999-11-30 | Gergely Gerhard | Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation |
EE04039B1 (et) * | 1995-03-02 | 2003-06-16 | R.P. Scherer Limited | Farmatseutiline kompositsioon peroraalseks manustamiseks, selle valmistamismeetod ja kasutamine |
-
1995
- 1995-09-20 IL IL11535795A patent/IL115357A/xx not_active IP Right Cessation
-
1996
- 1996-09-18 US US09/043,475 patent/US6126968A/en not_active Expired - Lifetime
- 1996-09-18 DE DE69637096T patent/DE69637096T2/de not_active Expired - Lifetime
- 1996-09-18 AT AT96930344T patent/ATE362755T1/de active
- 1996-09-18 JP JP51411997A patent/JP4108750B2/ja not_active Expired - Lifetime
- 1996-09-18 DK DK96930344T patent/DK0858328T3/da active
- 1996-09-18 HU HU9802999A patent/HU225859B1/hu unknown
- 1996-09-18 WO PCT/IL1996/000115 patent/WO1997012583A2/en active IP Right Grant
- 1996-09-18 EP EP96930344A patent/EP0858328B1/en not_active Expired - Lifetime
- 1996-09-18 CA CA002232310A patent/CA2232310C/en not_active Expired - Lifetime
- 1996-09-18 ES ES96930344T patent/ES2287940T3/es not_active Expired - Lifetime
- 1996-09-18 AU AU69427/96A patent/AU728524B2/en not_active Expired
- 1996-09-18 PT PT96930344T patent/PT858328E/pt unknown
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008519834A (ja) * | 2004-11-10 | 2008-06-12 | テバ ファーマシューティカル インダストリーズ リミティド | 低水溶性薬物とともに使用することによく適した圧縮固体状投与形態の製造方法およびそれにより製造された圧縮固体状投与形態 |
US8367106B2 (en) | 2004-11-10 | 2013-02-05 | Teva Pharmaceutical Industries, Ltd. | Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby |
US8367105B2 (en) | 2004-11-10 | 2013-02-05 | Teva Pharmaceutical Industries, Ltd. | Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby |
US8597666B2 (en) | 2004-11-10 | 2013-12-03 | Teva Pharmaceutical Industries, Ltd. | Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby |
JP2013509359A (ja) * | 2009-10-29 | 2013-03-14 | 重▲慶▼医葯工▲業▼研究院有限責任公司 | 安定なラサギリン組成物 |
JP2014534196A (ja) * | 2011-10-10 | 2014-12-18 | テバ ファーマシューティカル インダストリーズ リミティド | R(+)−n−ホルミル−プロパルギル−アミノインダン |
Also Published As
Publication number | Publication date |
---|---|
PT858328E (pt) | 2007-08-20 |
US6126968A (en) | 2000-10-03 |
WO1997012583A2 (en) | 1997-04-10 |
CA2232310C (en) | 2008-01-08 |
EP0858328A4 (en) | 2001-07-11 |
DE69637096T2 (de) | 2008-01-31 |
JP4108750B2 (ja) | 2008-06-25 |
IL115357A0 (en) | 1995-12-31 |
HU225859B1 (en) | 2007-11-28 |
CA2232310A1 (en) | 1997-04-10 |
IL115357A (en) | 2000-01-31 |
EP0858328A2 (en) | 1998-08-19 |
AU6942796A (en) | 1997-04-28 |
HUP9802999A2 (hu) | 1999-04-28 |
ES2287940T3 (es) | 2007-12-16 |
DE69637096D1 (de) | 2007-07-05 |
HUP9802999A3 (en) | 1999-05-28 |
DK0858328T3 (da) | 2007-09-03 |
EP0858328B1 (en) | 2007-05-23 |
ATE362755T1 (de) | 2007-06-15 |
AU728524B2 (en) | 2001-01-11 |
WO1997012583A3 (en) | 1997-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11512736A (ja) | N−プロパルギル−1−アミノインダンを含有する安定な組成物 | |
US6384020B1 (en) | Rapid immediate release oral dosage form | |
US5731000A (en) | Stabilized pharmaceutical composition containing bupropion | |
US6106861A (en) | Multiparticulate tablet disintegrating in less than 40 seconds in the mouth | |
CA2378469C (en) | An oral solid composition comprising carbidopa, levodopa and entacapone | |
US8741342B2 (en) | Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa | |
PL196668B1 (pl) | Zastosowanie ranolazyny do wytwarzania kompozycji farmaceutycznej o przedłużonym uwalnianiu | |
JP4619537B2 (ja) | 架橋セルロース誘導体とエンタカポンもしくはニトカポンとを含有する医薬組成物 | |
US20120202820A1 (en) | Pharmaceutical composition having the active substances metformin and sitagliptin or vildagliptin | |
JP2523726B2 (ja) | 固体組成物およびその製造方法 | |
US20030044462A1 (en) | Sustained release tablets containing bupropion hydrochloride | |
CZ291999B6 (cs) | Tableta pro léčbu migrény a způsob její přípravy | |
US20030147957A1 (en) | Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core | |
CA2482114C (en) | Solid dosage form comprising caffeine | |
AU3511201A (en) | Stable compositions containing N-propargyl-1-aminoidan | |
WO2005016315A1 (en) | Pharmaceutical compositions of nateglinide and a high amount of a water-soluble filler | |
WO2007113371A1 (en) | Pharmaceutical composition and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070508 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070808 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071002 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080131 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080221 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080304 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080403 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110411 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120411 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130411 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140411 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |